Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Davis Polk Advises Centogene N.V. on Its Initial Public Offering
Davis Polk advised Centogene N.V. on its $56 million initial public offering of 4,000,000 of its common shares. In addition,…
RAPT Therapeutics, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with a $38.4 million initial public offering of common stock of RAPT…
Progyny $149.5 Million Initial Public Offering and Nasdaq Listing
Davis Polk advised the underwriters on the SEC-registered initial public offering by Progyny, Inc. of 11,500,000 common…
Davis Polk Advises Charles River Laboratories International, Inc. on Its $500 Million Notes Offering
Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of …
Innate Pharma $79 Million U.S. Initial Public Offering of ADS on Nasdaq and Concurrent Private Placement
Davis Polk advised the underwriters in connection with an initial public offering of 8,047,227 American Depositary Shares of…
Natera, Inc. $230 Million Follow-On Public Offering
Davis Polk advised the several underwriters in connection with the follow-on offering of 6,571,428 shares of common…
BioNTech SE Initial Public Offering on Nasdaq
Davis Polk advised the underwriters in connection with the $150 million initial public offering of 10,000,000 American…
Aprea Therapeutics, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with the $97.75 million initial public offering of 6,516,667 shares of…
Top-Up Placing of Shares in Innovent Biologics, Inc.
Davis Polk advised the placing agents for the top-up placement of up to 97,000,000 shares in Innovent Biologics, Inc. for a…
BioXcel Therapeutics, Inc. $18.9 Million Common Stock Offering
Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,303…